Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Isoform 1: Cytoplasm. Membrane; Peripheral membrane protein. Nucleus. Note=Found predominantly in the cytoplasm and with less amounts nuclear or membrane-associated. Colocalizes with ADRB2 at the cell membrane.; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Nucleus. Note=Equally distributed between the nucleus and the cytoplasm but not membrane-associated. |
Domain |
PF01847 VHL beta domain PF17211 VHL box domain |
Function |
Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2. |
Biological Process |
GO:0001666 response to hypoxia GO:0031647 regulation of protein stability GO:0036293 response to decreased oxygen levels GO:0036294 cellular response to decreased oxygen levels GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress GO:0043620 regulation of DNA-templated transcription in response to stress GO:0050821 protein stabilization GO:0061418 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0070482 response to oxygen levels GO:0071453 cellular response to oxygen levels GO:0071456 cellular response to hypoxia GO:0097201 negative regulation of transcription from RNA polymerase II promoter in response to stress |
Molecular Function |
GO:0004842 ubiquitin-protein transferase activity GO:0008134 transcription factor binding GO:0019787 ubiquitin-like protein transferase activity GO:0061630 ubiquitin protein ligase activity GO:0061659 ubiquitin-like protein ligase activity |
Cellular Component |
GO:0000151 ubiquitin ligase complex GO:0000153 cytoplasmic ubiquitin ligase complex GO:0030891 VCB complex |
KEGG |
hsa04066 HIF-1 signaling pathway hsa04120 Ubiquitin mediated proteolysis |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-983168: Antigen processing R-HSA-2262749: Cellular response to hypoxia R-HSA-2262752: Cellular responses to stress R-HSA-983169: Class I MHC mediated antigen processing & presentation R-HSA-168256: Immune System R-HSA-1234176: Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha R-HSA-1234174: Regulation of Hypoxia-inducible Factor (HIF) by oxygen |
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between VHL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between VHL and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of VHL in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of VHL in various data sets.
|
Points in the above scatter plot represent the mutation difference of VHL in various data sets.
|
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VHL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VHL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VHL. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VHL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of VHL expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between VHL and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | VHL |
Name | von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
Aliases | VHL1; von Hippel-Lindau syndrome; von Hippel-Lindau tumor suppressor; RCA11; pVHL; elongin binding protein; ...... |
Chromosomal Location | 3p25.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting VHL collected from DrugBank database. |
There is no record. |